Volume 25 - Issue 5 - May 2017
News
News
05/04/2017
The FDA has accepted for review the supplemental New Drug Application (sNDA) for tofacitinib citrate (Xeljanz, Pfizer) 5mg twice daily (BID) for the treatment of adult patients with active psoriatic arthritis (PsA).
The FDA has accepted for review the supplemental New Drug Application (sNDA) for tofacitinib citrate (Xeljanz, Pfizer) 5mg twice daily (BID) for the treatment of adult patients with active psoriatic arthritis (PsA).
The FDA has accepted for review...
05/04/2017
The Dermatologist
News
05/03/2017
This April advocates around the globe launched the first Contact Dermatitis Awareness Month.
This April advocates around the globe launched the first Contact Dermatitis Awareness Month.
This April advocates around the...
05/03/2017
The Dermatologist
News
04/20/2017
Women who consume an increased amount of alcohol are at a higher risk of developing rosacea, according to a recent study.
Women who consume an increased amount of alcohol are at a higher risk of developing rosacea, according to a recent study.
Women who consume an increased...
04/20/2017
The Dermatologist
Interactive Features
FDA Alerts
04/24/2017
The infliximab biosimilar product infliximab-abda (Renflexis, Samsung Bioepis) has been approved for numerous indications, including Crohn’s disease, ulcerative colitis, rheumatoid arthritis (in combination with methotrexate), ankylosing...
The infliximab biosimilar product infliximab-abda (Renflexis, Samsung Bioepis) has been approved for numerous indications, including Crohn’s disease, ulcerative colitis, rheumatoid arthritis (in combination with methotrexate), ankylosing...
The infliximab biosimilar...
04/24/2017
The Dermatologist
04/13/2017
Recent research suggests that physicians split their time evenly between seeing patients and desktop medicine each day.
Recent research suggests that physicians split their time evenly between seeing patients and desktop medicine each day.
Recent research suggests that...
04/13/2017
The Dermatologist